Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
MIG Capital is a venture capital firm founded in 2004 and headquartered in Munich, Germany. The firm specializes in supporting founders in the deep tech and life sciences sectors, providing not only capital but also personal support and access to a vast network of industry contacts. This unique approach has positioned MIG Capital as one of Germany's leading VC investors, particularly noted for its early investment in BioNTech, which has become a significant player in the biotechnology space.
As of now, MIG Capital manages over €1.3 billion in assets across 18 funds, with a portfolio comprising approximately 50 companies. The firm has achieved 25 partial exits and 4 IPOs, including notable companies like BioNTech and NFON. Its funding model is distinctive, relying on over 60,000 private retail investors, which allows for long-duration capital without the typical pressures associated with institutional investors.
MIG Capital primarily invests in the sectors of deep tech and life sciences. Within deep tech, the firm focuses on advanced computing, digitalization & IoT, energy & environment, and new materials. In the life sciences sector, MIG Capital targets bio-pharmaceutical therapeutics, medical technology, and digital health. The firm typically invests between €1 million and €10 million, with a sweet spot around €3 million to €5 million, making it well-suited for seed-stage investments.
The firm’s investment strategy emphasizes identifying breakthrough technologies and supporting innovative companies that are developing real solutions in their respective fields. MIG Capital's unique position as a retail venture capital investor in Germany allows it to engage deeply with the startup ecosystem, providing not just financial backing but also mentorship and operational support.
MIG Capital's portfolio includes a diverse range of companies, showcasing its commitment to deep tech and life sciences. Notable companies in its portfolio include:
Other notable exits include Siltectra, acquired by Infineon, Hemovent, acquired by MicroPort, and BRAIN, NFON, and Immatics, which all achieved IPOs. The firm has invested over €680 million across its portfolio, demonstrating its active engagement in the startup ecosystem.
Michael Motschmann: Managing Partner with extensive experience in venture capital and a focus on deep tech investments.
Kristian Schmidt-Garve, LL.M.: Managing Partner specializing in legal and financial aspects of venture investments.
Dr. Nicolas Rose-André: Investment Manager with a background in biotechnology and life sciences.
Andreas Kastenbauer, MBA: Partner with expertise in business development and strategic investments.
Dr. Fei Tian: Principal focused on technology-driven startups and innovation.
Jürgen Kosch: Managing Partner with a strong track record in venture capital.
Frederick Michna: Principal with experience in operational support for portfolio companies.
Christina Vogt-Sasse: Senior Associate involved in deal sourcing and analysis.
Dr. Søren Hein: Venture Partner with expertise in medical technology and healthcare.
Dr. Matthias Kromayer: Managing Partner with a focus on strategic investments in deep tech.
To pitch to MIG Capital, founders should use the preferred channel available on their website at mig.ag. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, and financial projections. The firm typically responds to inquiries within a few weeks, and while warm introductions are beneficial, they are not strictly necessary.
On November 20, 2025, MIG Capital led a €16 million seed financing round for AI hardware startup NcodiN. This investment reflects the firm's commitment to supporting innovative technology companies.
On July 24, 2025, MIG Capital announced it led a CHF 7.75 million seed financing for Astra Therapeutics, further expanding its portfolio in the life sciences sector.
On June 16, 2025, MIG Capital disclosed €50 million in Series A funding for Look Up, showcasing its active role in financing emerging startups.
What are MIG Capital's investment criteria?
MIG Capital focuses on seed-stage investments in deep tech and life sciences sectors. They typically invest between €1 million and €10 million, with a preference for amounts around €3 million to €5 million. The firm looks for innovative companies that are developing breakthrough technologies.
How can founders apply or pitch to MIG Capital?
Founders can pitch their ideas through the MIG Capital website at mig.ag. It is advisable to include a detailed business plan and financial projections in the pitch deck.
What makes MIG Capital different from other venture capital firms?
MIG Capital is unique as it is funded entirely by over 60,000 private retail investors, allowing for a long-term investment horizon without the pressure of institutional LPs. This model enables the firm to provide not just capital but also personal support and access to a vast network.
What is the geographic scope of MIG Capital's investments?
The firm primarily invests in Europe, focusing on innovative companies within the deep tech and life sciences sectors.
What is MIG Capital's post-investment involvement like?
MIG Capital provides ongoing support to its portfolio companies, including mentorship, operational assistance, and access to its extensive network of industry contacts. This support helps companies navigate challenges and accelerate their growth.
What is the size of MIG Capital's funds?
MIG Capital has committed over €1.2 billion across multiple funds, with a total invested amount exceeding €680 million in approximately 50 companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.